Treatment of essential thrombocythemia with special emphasis on leukemogenic risk

Annals of Hematology

Volumn 78, Issue 9, 1999, Pages 389-392

  Finazzi, G ^a   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; Leukemogenic risk; Treatment

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CYTOTOXIC AGENT; HYDROXYUREA;

ACUTE LEUKEMIA; BLAST TRANSFORMATION; BLEEDING; CANCER RISK; CYTOGENETICS; CYTOTOXICITY; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTHEMIA; THROMBOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; HYDROXYUREA; LEUKEMIA; MIDDLE AGED; RISK FACTORS; THROMBOCYTOSIS; THROMBOSIS;

EID: 0032872239     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050536     Document Type: Short Survey

References (25)

1. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69-76
2. Barbui T, Finazzi G, Dupuy E, Kiladijan JJ, Brière J (1996) Treatment strategies in essential thrombocythemia. Leuk Lymphoma 22 [Suppl 1]: 149-160
3. Barbui T, Finazzi G, Ruggeri M, Rodeghiero F (1998) Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: long-term results of a randomized clinical trial. Blood 92 [Suppl 1]: 489a (abstr)
4. Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, bairey O, Sulkes J, Shaklai M (1997) BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: clinical presentation. Blood 90:2768-2771
5. Boivin P (1993) Indications, procedure and results for the treatment of polycythemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 35:491-498
6. Brusamolino E, Canevari A, Salvaneschi L, et al (1984) Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat Reports 68:1339-1342
7. Chintagumpala MM, Steuber CP, Mahoney DH jr, Ogden AK, Fernbach DJ (1991) Essential thrombocythemia in a child: management with anagrelide. Am J Pediatr Hematol Oncol 13:52-56
8. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562
9. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 332:1132-1136
10. Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22 [Suppl 1]: 135-142
11. Löfvenberg E, Nordenson I, Walhlin A (1990) Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 49:57-67
12. Marasca R, Luppi M, Zucchini P, Longo G, Torelli G, Emilia G (1998) Might essential thrombocythemia carry Ph anomaly? Blood 91:3084-3089
13. Mazzucconi MG, Francesconi M, Chistolini A, et al. (1986) Pipobroman therapy of essential thrombocythemia. Scand J Haematol 37:306-309
14. Michiels JJ, Abels J, Steketee J, Van Vliet HHDM, Vuzevski VD (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471
15. Mitus AJ, Barbui T, Shulman LN, Rosenthal DS, Viero P, Cortelazzo S, Schafer AI (1990) Hemostatic complications in young patients with essential thrombocythemia. Am J Med 88:371-375
16. Murphy S, Peterson P, Hand H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34:29-39
17. Najean Y, Rain JD for the French Polycythemia Study Group (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370-3719
18. Nand S, Stock W, Godwin J, Fisher SG (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 52:42-46
19. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 103:772-777
20. Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M(1994) Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta Haematol 91:84-88
21. Sterkers Y, Preudhomme C, Lai JL, Demory J-L, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea. Blood 91:616-622
22. Tefferi A, Silverstein MN, Petitt R, Mesa RA, Solberg LA (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Haemost 23:379-383
23. Van de Pette JEW, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G (1986) Primary thrombocythemia treated with busulphan. Br J Haematol 62:229-237
24. Van Genderen PJJ, Michiels JJ (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73-77
25. Weinfield A, Swolin B, Westin J (1994) Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52:134-139